Roche offloads lebrikizumab to Dermira
Roche and its Genentech Inc. division licensed Dermira Inc. exclusive global development and commercialization rights to their Phase II antibody lebrikizumab.
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
- Large Molecule
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
- Reverse Licensing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.